Volpara delivers better breast imaging, via Azure
- 15 July, 2016 09:35
Wellington-based medical software company, Volpara Solutions, has launched VolparaEnterprise, running in Microsoft’s Azure cloud. The company says the software helps breast imaging providers deliver high quality, personalised breast screening, providing “real-time quality assurance and performance monitoring through dynamic, interactive dashboards.”
According to Volpara, the software “enables breast imaging providers to perform rapid quality control checks to optimise the productivity and efficiency of imaging resources, to help reduce costs through the reduction of retakes, to increase staff effectiveness, and to provide objective evidence to demonstrate compliance and quality of care.”
The company says the software has already helped improve productivity, quality assurance and cancer detection rates. “A facility discovered that a mammography system was using an incorrect dose setting, over-exposing patients compared to the same machine type and same patient body habitus in similar facilities,” Volpara said in a statement. Another facility “discovered that it did not need to purchase an additional mammography machine because the software demonstrated that utilisation was below the break-even point.”
“VolparaEnterprise software offers the first comprehensive tool to analyse clinical, quality, and business data that impact nearly every aspect of a breast imaging practice,” Bruce F Schroeder, an MD with Carolina Breast Imaging Specialists in North Carolina, said in a statement provided by Volpara.
“There is a tremendous amount of data that we've never been to access easily. The ability to track trends for hundreds of quality metrics over time can dramatically enhance our ability to maintain quality patient care as well as reduce the amount of time our staff spends on quality assurance.”
Volpara Solutions’ parent company, Volpara Health Technologies, listed on the ASX in April, raising NZ$10 million from the issue of 20 million shares at 50 cents each, giving it a market capitalisation of NZ$61 million. It says its software is used in 35 countries.
Earlier in 2016 the company was awarded Frost & Sullivan’s global award for competitive strategy innovation and leadership “for innovative strategies in strengthening its brand and thereby, demand for its products, in the intensely competitive breast density assessment solutions market.”